scout
|Videos|July 7, 2017

Results for the Combination of Ublituximab and Ibrutinib in CLL

Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME